関連レポート

腫瘍溶解性ウイルス免疫療法の世界市場：2031年予測

出版元：Transparency Market Research  出版元について

発行年：2024年4月

定価：Single User License $5795 Multi User License $8795 Corporate User License $11795

ご請求は円換算（お見積り日TTSレート）となります。

ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。

納品形態：PDF by Email

当調査レポートは英文 112ページになります。

商品コード：TMR251

当レポートは発行年月に関わらず、受注の都度、最新情報にアップデートしてお届けいたします。ご希望情報の追加等もご相談可能です。

レポート紹介

抗HER2抗体の世界市場規模は2023年で90億ドル、2034年末までに157億ドルへと拡大し、2024年から2034年にかけての市場の平均年成長率は5.1%で推移することが見込まれています。

当レポートでは、抗HER2抗体の市場予測-2034年、各種セグメント別市場分析(治療薬タイプ別、国地域別、等)、市場ダイナミクス、パイプライン分析、主要企業プロフィールなどの情報を盛り込み、概略以下の構成でお届けいたします。

【レポート構成概要】
■抗HER2抗体の世界市場予測2020-2034年
・市場規模(US$)

■治療薬タイプ別、市場-2034年
・トラスツズマブ
・ラパチニブ
・アドトラスツズマブ エムタンシン
・ペルツズマブ
・エベロリムス
※(市場規模US$)

■主要国地域別市場-2034年
北米
・米国、カナダ
欧州
・英国、ドイツ、フランス、イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド、オーストラリア/ニュージーランド
・その他アジア太平洋
中南米
・ブラジル、メキシコ
・その他中南米
中東アフリカ
・GCC諸国、南アフリカ
・その他中東アフリカ
※地域別に各種セグメント別の細分化データ掲載、詳細は目次参照

■市場分析
・市場ダイナミクス（促進要因、障壁、機会）
・パイプライン分析
・主要製品/ブランド分析
・競合状況

■抗HER2抗体の主要企業プロフィール動向
・Novartis AG
・Pfizer, Inc.
・F. Hoffmann-La Roche Ltd.
・Abnova Corporation
・InvivoGen
・Celltrion, Inc.
・Biocon
・Novus Biologicals

（全112頁）

Table of Contents (英文詳細目次）

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global HER2 Antibodies Market

4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global HER2 Antibodies Market Analysis and Forecast, 2020-2034

5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global HER2 Antibodies Market Analysis and Forecast, by Type of Treatment Drugs
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type of Treatment Drugs, 2020-2034
6.3.1. Trastuzumab
6.3.2. Lapatinib
6.3.3. Ado-trastuzumab Emtansine
6.3.4. Pertuzumab
6.3.5. Everolimus
6.4. Market Attractiveness Analysis, by Type of Treatment Drugs

7. Global HER2 Antibodies Market Analysis and Forecast, by Region
7.1. Key Findings
7.2. Market Value Forecast, by Region, 2020-2034
7.2.1. North America
7.2.2. Europe
7.2.3. Asia Pacific
7.2.4. Latin America
7.2.5. Middle East & Africa
7.3. Market Attractiveness Analysis, by Region

8. North America HER2 Antibodies Market Analysis and Forecast
8.1. Introduction
8.2. Key Findings
8.3. Market Value Forecast, by Type of Treatment Drugs, 2020-2034
8.3.1. Trastuzumab
8.3.2. Lapatinib
8.3.3. Ado-trastuzumab Emtansine
8.3.4. Pertuzumab
8.3.5. Everolimus
8.4. Market Value Forecast, by Country, 2020-2034
8.4.1. U.S.
8.4.2. Canada
8.5. Market Attractiveness Analysis
8.5.1. By Type of Treatment Drugs
8.5.2. By Country

9. Europe HER2 Antibodies Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Type of Treatment Drugs, 2020-2034
9.3.1. Trastuzumab
9.3.2. Lapatinib
9.3.3. Ado-trastuzumab Emtansine
9.3.4. Pertuzumab
9.3.5. Everolimus
9.4. Market Value Forecast, by Country/Sub-region, 2020-2034
9.4.1. Germany
9.4.2. U.K.
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Rest of Europe
9.5. Market Attractiveness Analysis
9.5.1. By Type of Treatment Drugs
9.5.2. By Country/Sub-region

10. Asia Pacific HER2 Antibodies Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Type of Treatment Drugs, 2020-2034
10.3.1. Trastuzumab
10.3.2. Lapatinib
10.3.3. Ado-trastuzumab Emtansine
10.3.4. Pertuzumab
10.3.5. Everolimus
10.4. Market Value Forecast, by Country/Sub-region, 2020-2034
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Australia & New Zealand
10.4.5. Rest of Asia Pacific
10.5. Market Attractiveness Analysis
10.5.1. By Type of Treatment Drugs
10.5.2. By Country/Sub-region

11. Latin America HER2 Antibodies Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Type of Treatment Drugs, 2020-2034
11.3.1. Trastuzumab
11.3.2. Lapatinib
11.3.3. Ado-trastuzumab Emtansine
11.3.4. Pertuzumab
11.3.5. Everolimus
11.4. Market Value Forecast, by Country/Sub-region, 2020-2034
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Rest of Latin America
11.5. Market Attractiveness Analysis
11.5.1. By Type of Treatment Drugs
11.5.2. By Country/Sub-region

12. Middle East & Africa HER2 Antibodies Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Type of Treatment Drugs, 2020-2034
12.3.1. Trastuzumab
12.3.2. Lapatinib
12.3.3. Ado-trastuzumab Emtansine
12.3.4. Pertuzumab
12.3.5. Everolimus
12.4. Market Value Forecast, by Country/Sub-region, 2020-2034
12.4.1. GCC Countries
12.4.2. South Africa
12.4.3. Rest of Middle East & Africa
12.5. Market Attractiveness Analysis
12.5.1. By Type of Treatment Drugs
12.5.2. By Country/Sub-region

13. Competition Landscape
13.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
13.2. Market Share Analysis, by Company (2023)
13.3. Company Profiles
13.3.1. Novartis AG
13.3.1.1. Company Overview
13.3.1.2. Product Portfolio
13.3.1.3. SWOT Analysis
13.3.1.4. Financial Overview
13.3.1.5. Strategic Overview
13.3.2. Pfizer, Inc.
13.3.2.1. Company Overview
13.3.2.2. Product Portfolio
13.3.2.3. SWOT Analysis
13.3.2.4. Financial Overview
13.3.2.5. Strategic Overview
13.3.3. F. Hoffmann-La Roche Ltd.
13.3.3.1. Company Overview
13.3.3.2. Product Portfolio
13.3.3.3. SWOT Analysis
13.3.3.4. Financial Overview
13.3.3.5. Strategic Overview
13.3.4. Abnova Corporation
13.3.4.1. Company Overview
13.3.4.2. Product Portfolio
13.3.4.3. SWOT Analysis
13.3.4.4. Financial Overview
13.3.4.5. Strategic Overview
13.3.5. InvivoGen
13.3.5.1. Company Overview
13.3.5.2. Product Portfolio
13.3.5.3. SWOT Analysis
13.3.5.4. Financial Overview
13.3.5.5. Strategic Overview
13.3.6. Celltrion, Inc.
13.3.6.1. Company Overview
13.3.6.2. Product Portfolio
13.3.6.3. SWOT Analysis
13.3.6.4. Financial Overview
13.3.6.5. Strategic Overview
13.3.7. Biocon
13.3.7.1. Company Overview
13.3.7.2. Product Portfolio
13.3.7.3. SWOT Analysis
13.3.7.4. Financial Overview
13.3.7.5. Strategic Overview
13.3.8. Novus Biologicals
13.3.8.1. Company Overview
13.3.8.2. Product Portfolio
13.3.8.3. SWOT Analysis
13.3.8.4. Financial Overview
13.3.8.5. Strategic Overview

List of Tables

Table 01: Global HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2020-2034

Table 02: Global HER2 Antibodies Market Size (US$ Mn) Forecast, by Region, 2020-2034

Table 03: North America HER2 Antibodies Market Size (US$ Mn) Forecast, by Country, 2020-2034

Table 04: North America HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2020-2034

Table 05: Europe HER2 Antibodies Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 06: Europe HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2020-2034

Table 07: Asia Pacific HER2 Antibodies Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 08: Asia Pacific HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2020-2034

Table 09: Latin America HER2 Antibodies Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 10: Latin America HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2020-2034

Table 11: Middle East & Africa HER2 Antibodies Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 12: Middle East & Africa HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2020-2034

List of Figures

Figure 01: Global HER2 Antibodies Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2034

Figure 02: Global HER2 Antibodies Market Revenue (US$ Mn), by Type of Treatment Drugs, 2023

Figure 03: Global HER2 Antibodies Market Value Share, by Type of Treatment Drugs, 2023

Figure 04: Global HER2 Antibodies Market Value Share, by Region, 2023

Figure 05: Global HER2 Antibodies Market Value (US$ Mn) Forecast, 2024-2034

Figure 06: Global HER2 Antibodies Market Value Share Analysis, by Type of Treatment Drugs, 2023 and 2034

Figure 07: Global HER2 Antibodies Market Attractiveness Analysis, by Type of Treatment Drugs, 2024-2034

Figure 08: Global HER2 Antibodies Market Value Share Analysis, by Region, 2023 and 2034

Figure 09: Global HER2 Antibodies Market Attractiveness Analysis, by Region, 2023-2034

Figure 10: North America HER2 Antibodies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 11: North America HER2 Antibodies Market Attractiveness Analysis, by Country, 2024-2034

Figure 12: North America HER2 Antibodies Market Value Share Analysis, by Country, 2023 and 2034

Figure 13: North America HER2 Antibodies Market Value Share Analysis, by Type of Treatment Drugs, 2023 and 2034

Figure 14: North America HER2 Antibodies Market Attractiveness Analysis, by Type of Treatment Drugs, 2024-2034

Figure 15: Europe HER2 Antibodies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 16: Europe HER2 Antibodies Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 17: Europe HER2 Antibodies Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 18: Europe HER2 Antibodies Market Value Share Analysis, by Type of Treatment Drugs, 2023 and 2034

Figure 19: Europe HER2 Antibodies Market Attractiveness Analysis, by Type of Treatment Drugs, 2024-2034

Figure 20: Asia Pacific HER2 Antibodies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 21: Asia Pacific HER2 Antibodies Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 22: Asia Pacific HER2 Antibodies Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 23: Asia Pacific HER2 Antibodies Market Value Share Analysis, by Type of Treatment Drugs, 2023 and 2034

Figure 24: Asia Pacific HER2 Antibodies Market Attractiveness Analysis, by Type of Treatment Drugs, 2024-2034

Figure 25: Latin America HER2 Antibodies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 26: Latin America HER2 Antibodies Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 27: Latin America HER2 Antibodies Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 28: Latin America HER2 Antibodies Market Value Share Analysis, by Type of Treatment Drugs, 2023 and 2034

Figure 29: Latin America HER2 Antibodies Market Attractiveness Analysis, by Type of Treatment Drugs, 2024-2034

Figure 30: Middle East & Africa HER2 Antibodies Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 31: Middle East & Africa HER2 Antibodies Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 32: Middle East & Africa HER2 Antibodies Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 33: Middle East & Africa HER2 Antibodies Market Value Share Analysis, by Type of Treatment Drugs, 2023 and 2034

Figure 34: Middle East & Africa HER2 Antibodies Market Attractiveness Analysis, by Type of Treatment Drugs, 2024-2034

△ 一番上に戻る